Insights extracted from a panel discussion at PTMC – Portugal Medical Cannabis on September 10, 2026. Panellists: Bennet Constantin (Sanity Group GmbH), Ana Serrato (Chairwoman, European Medicinal Cannabis Association (EUMCA)), Daniel Cook (CEO, True Terpenes) and Alfredo Pascual, CFA (Head of Strategy & Corporate Development, Cannamedical). Moderated by Ben Stevens (Editor, Business of Cannabis).
Why Capital Discipline Is the New Currency in European Cannabis
For years, medical cannabis pitch decks ran on a single promise: massive addressable markets, imminent legalisation, and valuations that assumed both would arrive at once. At PTMC 2026, a panel on capital efficiency in the supply chain opened with a blunter question: is the industry actually maturing, or is that just a phrase journalists reach for when the hype cools down?
The panel’s answer, delivered from four very different vantage points, was that something real has shifted. Germany’s reclassification of cannabis away from narcotics law under the Cannabis Gesetz (CanG) on 1 April 2024 turned a market many had written off as a disappointment into the fastest-growing medical cannabis market in Europe. That single regulatory change reset the economics for an entire continent, and it is the backdrop against which nearly every deal discussed on stage, from Organigram’s acquisition of German operator Sanity Group, to Canadian retailer High Tide’s majority acquisition of German wholesale importer Remexian Pharma, to Curaleaf’s ongoing bid for Aurora Cannabis, has to be read.
It also explains why capital is moving differently than it did in 2021 and 2022. Vertical integration, once the default strategy for any company chasing a “seed to patient” story, is giving way to companies picking a specific role in the supply chain and defending it well. Investors, meanwhile, are less interested in total addressable market slides and more interested in cash flow, gross margin per gram, and whether a company can survive a price decline without burning through its balance sheet. For an industry that spent its first decade selling a dream, PTMC 2026’s capital efficiency panel was a useful gut check on how much of that dream has actually been converted into a functioning business.
The Numbers Behind the Panel
The panel was unusually specific for an industry that often deals in projections rather than results. Some of the sharpest figures shared on stage, and the secondary data points that corroborate them:
- Germany now has over one million patients actively buying medical cannabis, with Alfredo Pascual estimating a further five million regular users still sourcing from the illicit market, a conversion opportunity he framed as the real growth story behind the market’s expansion.
- Organigram’s acquisition of Sanity Group closed in April 2026 at a value of up to €250 million, with an upfront payment of €107.3 million (€78 million in cash and €29.3 million in stock) and up to a further €120 million tied to performance milestones, a structure the panel pointed to as proof that acquirers are now paying for market share and operational synergy rather than a growth narrative.
- Daniel Cook estimated that roughly $6 billion of near-term cash stress sits across publicly listed US cannabis operators, split roughly evenly across receivables, Section 280E tax exposure, and near-term debt, a structural squeeze that continues to push operators toward capital discipline whether they want it or not.
- Jazz Pharmaceuticals’ $7.2 billion acquisition of GW Pharmaceuticals in 2021, which brought the epilepsy treatment Epidyolex into Jazz’s portfolio, was repeatedly cited as the ceiling the industry has not come close to testing again, with Ana Serrato noting that Epidyolex’s sales are now nearing the billion dollar mark for pediatric epilepsy alone, evidence of what a fully realised clinical and regulatory pathway in cannabinoid medicine can eventually be worth.
- Across Germany, the UK, and Poland, the panel described the same pattern: rising sales volume paired with falling price per gram, with volume growth so far outpacing the price decline enough to keep overall market value climbing.
- The panel’s reference to smaller, supply-chain-driven deals held up under scrutiny too: High Tide’s 2025 acquisition of a 51% stake in German wholesale importer Remexian Pharma, for roughly €26.4 million, implied an enterprise value of €53.4 million, a deal built entirely around filling a missing piece of the supply chain rather than a growth story.
5 Key Takeaways
- Profitability, not projections, is now the price of admission for M&A. The panel was blunt that a deal like Organigram’s acquisition of Sanity Group would not have happened at the same valuation, or arguably at all, three or four years ago. Buyers are paying for demonstrated market share, production synergy, and a balance sheet that can support growth, not a story about where the market might be in five years.
- Vertical integration is losing ground to specialisation. Ana Serrato argued that the industry is moving away from the “seed to patient” model that dominated five years ago, with companies now choosing a specific role in the supply chain rather than trying to own every link in it. That focus is precisely what made businesses like Sanity Group attractive acquisition targets rather than acquisition risks.
- North American capital is arriving in Europe, but on Europe’s terms. Canadian and, increasingly, US operators are turning to European markets as a source of growth that their home markets can no longer provide alone. But the panel was clear that the pitches now landing with European investors are built on operational efficiency and profitability, not the “imaginary town” style projections that characterised the market five or six years ago.
- Big pharma is watching cannabinoids for pipeline reasons, not sentiment. With patent cliffs looming across their existing portfolios, pharmaceutical companies are assessing cannabinoid assets the same way they assess any other drug candidate: on regulatory feasibility, a credible clinical programme, and defensible intellectual property. Ana Serrato estimated that only a small fraction of medical cannabis companies, perhaps as few as 5%, will ever make that leap into full clinical development, with the rest remaining in early access and out-of-pocket markets.
- Regulatory alignment has become a capital efficiency strategy in its own right. From Portugal’s tightened reporting requirements to the UK’s Proceeds of Crime Act depressing risk appetite among major banks, the panel agreed that working proactively with regulators, rather than reacting to sudden rule changes, is now as important to protecting capital as any balance sheet decision. As the panel’s discussion of Germany’s swift, three day consultation window on off-label cannabinoid use showed, the rules can move faster than the industry expects.
Notable Quotes
"We are escaping a little bit of that concept from seed-to-patient, or that vertical integration that we heard around maybe five years ago. Companies are really electing which is their value, which is their proposal, which is their role in the whole chain."
"If we are not side by side with the regulators, the story can be shut down from one day to the other."
"I think the key factor for Sanity and Organigram is more that you have a synergy in terms of production and market reach and market excellence. It's not only about the cash that is on the bank account, which was a big amount for Sanity, one of the startups that had the most cash on the bank account."
"So I would think the future is with the product innovations, cannabis 2.0. If you can get an IP, if you can make a clinical study, if you can get a finished product on the market, it can go into blue oceans for new patients and get different demographics, I think that's where we should head at some point."
"I don't think it's a mature market. I hesitate to use the word maturing even. I think it's evolving. Cannabis companies over-invest in a broader array of activities than a normal business would, and that really presses them downward."
"If I were an investor in this space, I'd still be focused on cash flow and longevity, really building durable foundations. You can't get in on exit arbitrage, or try to time a little window of opportunity to get your money out. You have to have patience."
"The main driver of why this is happening now is Germany's reclassification of cannabis in April 2024. It meant massive growth in the German market, and now you have a bunch of companies on a runway to do 100-plus million in revenue, highly profitable, which was not even something someone was dreaming of back in 2020."
"In 2018, 2019, many companies were selling a dream. Here's a licence, this is an imaginary town, and it's going to be massive. That typically is not what excites European investors. What we are showing now is operational efficiency, market capture, companies being profitable, and that is when European investors start paying attention."
[From the audience during the Q&A session] "Regulators fear what regulators don't know, and they can close a market in a moment. We need to mitigate these risk factors by being much more serious about documentation and how we react to regulators."
English (UK)
Deutsch